Miami, FL (July 21, 2021) — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofin™, for the treatment of ‘Prolonged COVID-19 Symptoms’ (“Long Haulers”). [Read more…]
Charles River Snags Gene Therapy CDMO Vigene Biosciences for $292.5M
June 29, 2021, Wilmington, MA — Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Vigene Biosciences, Inc. for $292.5 million in cash, subject to customary closing adjustments. In addition to the initial purchase price, the transaction includes additional payments of up to $57.5 million, contingent on future performance. [Read more…]
denovoMATRIX acquires state grant for accelerating development of iPSC scale-up technologies
DRESDEN, Germany, June 28, 2021 — denovoMATRIX GmbH, a developer of technologies which enable high quality stem cell expansion, has received a grant from the State Bank of Saxony for the development of microcarriers designed for xeno-free induced pluripotent stem cell culture. The outlook for the technology is for applications in iPSC banking, allogenic therapies, as well as the clean meat industry.
Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of iPSC-based Therapies
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has reached an agreement to acquire RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs). Upon completion, the acquisition will build upon Catalent’s existing custom cell therapy process development and manufacturing capabilities with proprietary GMP cell lines for iPSC-based therapies. The deal will enable Catalent to offer the building blocks to scale iPSC-based cell therapies while reducing barriers to entry to the clinic for therapeutic companies and is expected to close before the end of 2021, subject to customary conditions. Financial details of the transaction have not been disclosed.
Leap forward in cell therapy manufacturing: data reveals highly reproducible stem cell expansion in 10L bioreactors, with exponential growth and preserved quality
TreeFrog Therapeutics announces the results of two runs of hiPSC amplification in 10L bioreactors at the Annual Meeting of the International Society for Stem Cell Research.
BORDEAUX, France, Jun. 21, 2021 — Today, French cell therapy company TreeFrog Therapeutics released data showing the mass production of human induced pluripotent stem cells (hiPSC) produced with their proprietary C-Stem™ technology in 10L bioreactors at the 2021 Annual Meeting of the International Society for Stem Cell Research (ISSCR). The data shows the output from two batches with indistinguishable expansion curves, demonstrating a high degree of reproducibility, while cell analysis showed conservation of stem cell quality. [Read more…]
- « Previous Page
- 1
- …
- 42
- 43
- 44
- 45
- 46
- …
- 96
- Next Page »